Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Autoimmune (1)
- Biologics (1)
- Breast (1)
- Breast Surgery (1)
- Breast Surgery Post Operative (1)
-
- Breast Surgery Post Operative Pyoderma Gangrenosum (1)
- Corticosteroids (1)
- IL-17 (1)
- Ixekizumab (1)
- Pityriasis rubra pilaris (1)
- Post Operative (1)
- Post Operative Pyoderma Gangrenosum (1)
- Postoperative Pyoderma Gangrenosum (1)
- Pyoderma Gangrenosum (1)
- Pyoderma Gangrenosum post breast surgery (1)
- Pyoderma Gangrenosum post surgery (1)
- Systematic Review (1)
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Post-Surgical Pyoderma Gangrenosum After Breast Surgery: A Case Series, Jahan Tajran, Daniella Anderson, Arif Chaudhry, Dennis Hammond
Post-Surgical Pyoderma Gangrenosum After Breast Surgery: A Case Series, Jahan Tajran, Daniella Anderson, Arif Chaudhry, Dennis Hammond
Medical Student Research Symposium
Background:
Pyoderma gangrenosum (PG) is a rare inflammatory cutaneous disorder that is thought to be due to innate immune system dysfunction, specifically of neutrophils. PG has been well documented in patients with autoimmune disorders like Ulcerative Colitis and Rheumatoid Arthritis. PG can also present in surgical patients, imitating a potential wound infection and necrotizing fasciitis. Although PG is a diagnosis of exclusion, prompt recognition is essential to attaining desired aesthetic outcomes, especially with breast involvement. We present a case series of four patients who developed PG following breast surgery. We analyze each patient’s medical history, symptoms, wound progression and management …
Use Of Biologics In Pityriasis Rubra Pilaris: A Case Report And Review Of The Literature, Elizabeth A. Warbasse, Taryn Huizenga Md
Use Of Biologics In Pityriasis Rubra Pilaris: A Case Report And Review Of The Literature, Elizabeth A. Warbasse, Taryn Huizenga Md
Medical Student Research Symposium
Pityriasis rubra pilaris (PRP) is an inflammatory papulosquamous disorder of unknown etiology. It is characterized by hyperkeratotic scaling plaques with an orange-red hue, “islands of sparing,” and palmoplantar keratoderma; it may cause erythroderma. There have been no completed controlled clinical trials for the treatment of PRP, and there are no FDA approved treatments at this time; most treatment evidence is derived from case reports. This review of the literature explores the use of various biologics which have been attempted for treatment of widespread or treatment resistant PRP. Some case reports have demonstrated efficacy of anti-IL-17 and anti-IL12/23 agents for PRP …